AU2020210869A1 - Methods of enhancing protection against organ and vascular injury, hematopoietic recovery and survival in response to total body radiation/chemical exposure - Google Patents

Methods of enhancing protection against organ and vascular injury, hematopoietic recovery and survival in response to total body radiation/chemical exposure Download PDF

Info

Publication number
AU2020210869A1
AU2020210869A1 AU2020210869A AU2020210869A AU2020210869A1 AU 2020210869 A1 AU2020210869 A1 AU 2020210869A1 AU 2020210869 A AU2020210869 A AU 2020210869A AU 2020210869 A AU2020210869 A AU 2020210869A AU 2020210869 A1 AU2020210869 A1 AU 2020210869A1
Authority
AU
Australia
Prior art keywords
subject
rwj
treated
chemotherapy
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020210869A
Other languages
English (en)
Inventor
Gary Eichenbaum
Sanchita GHOSH
Alfred Tonelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of AU2020210869A1 publication Critical patent/AU2020210869A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/196—Thrombopoietin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2020210869A 2019-01-25 2020-01-24 Methods of enhancing protection against organ and vascular injury, hematopoietic recovery and survival in response to total body radiation/chemical exposure Abandoned AU2020210869A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962796728P 2019-01-25 2019-01-25
US62/796,728 2019-01-25
PCT/US2020/015015 WO2020154637A1 (en) 2019-01-25 2020-01-24 Methods of enhancing protection against organ and vascular injury, hematopoietic recovery and survival in response to total body radiation/chemical exposure

Publications (1)

Publication Number Publication Date
AU2020210869A1 true AU2020210869A1 (en) 2021-08-19

Family

ID=69740564

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020210869A Abandoned AU2020210869A1 (en) 2019-01-25 2020-01-24 Methods of enhancing protection against organ and vascular injury, hematopoietic recovery and survival in response to total body radiation/chemical exposure

Country Status (11)

Country Link
US (2) US20200237872A1 (https=)
EP (1) EP3914281A1 (https=)
JP (1) JP7664163B2 (https=)
KR (1) KR20210119469A (https=)
CN (1) CN113660943A (https=)
AU (1) AU2020210869A1 (https=)
CA (1) CA3127458A1 (https=)
IL (1) IL285092A (https=)
MA (1) MA54821A (https=)
MX (1) MX2021008928A (https=)
WO (1) WO2020154637A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018306329B8 (en) 2017-07-26 2025-02-20 Janssen Pharmaceutica Nv Methods of protecting vascular integrity induced by targeted radiation therapy
MX2021008943A (es) * 2019-01-25 2021-11-04 Janssen Pharmaceutica Nv Metodos para mitigar la lesion hepatica y promover la hipertrofia hepatica, la regeneracion e injerto celular en conjunto con tratamientos de radiacion y/o radiomimeticos.
WO2023056444A1 (en) * 2021-10-01 2023-04-06 Janssen Pharmaceutica N.V. Methods of increasing progenitor cell production
WO2024095178A1 (en) 2022-11-01 2024-05-10 Janssen Pharmaceutica Nv Thrombopoietin mimetic for use in the treatment of acute liver failure

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU680422B2 (en) 1992-06-11 1997-07-31 Alkermes Controlled Therapeutics, Inc. Erythropoietin drug delivery system
US5354934A (en) 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
US7091311B2 (en) 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7723295B2 (en) 2003-08-28 2010-05-25 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
SG131110A1 (en) 2003-08-28 2007-04-26 Ortho Mcneil Pharm Inc Peptides and compounds that bind to thrombopoietin receptors
US20060210542A1 (en) 2004-08-16 2006-09-21 Yurkow Edward J Use of TPO mimetic compounds and pharmaceutical compositions in the treatment of anemia
US7615533B2 (en) 2004-08-16 2009-11-10 Janssen Pharmaceutica N.V. TPO peptide compounds for treatment of anemia
DK1984014T3 (da) 2006-02-14 2014-09-15 Janssen Pharmaceutica Nv Anvendelse af tpo-peptidforbindelser og farmaceutiske sammensætninger ved behandlingen af anæmi
ES2729622T3 (es) 2008-06-03 2019-11-05 Janssen Pharmaceutica Nv Péptido mimético de TPO para prevenir el desorden hematológico asociado al tratamiento contra el cáncer
CN104411316B (zh) * 2012-05-09 2018-05-01 坎泰克斯制药股份有限公司 骨髓抑制的治疗
US20140051631A1 (en) * 2012-08-17 2014-02-20 Francoise Porteu Pharmaceutical composition comprising tpo or an agonist of the tpo receptor
JP6150374B2 (ja) * 2012-11-15 2017-06-21 国立大学法人弘前大学 放射線被ばく治療剤及び放射線被ばく治療方法

Also Published As

Publication number Publication date
JP7664163B2 (ja) 2025-04-17
US20220168392A1 (en) 2022-06-02
US20200237872A1 (en) 2020-07-30
IL285092A (en) 2021-09-30
CN113660943A (zh) 2021-11-16
EP3914281A1 (en) 2021-12-01
WO2020154637A1 (en) 2020-07-30
JP2022519196A (ja) 2022-03-22
MA54821A (fr) 2021-12-01
WO2020154637A9 (en) 2020-08-27
CA3127458A1 (en) 2020-07-30
MX2021008928A (es) 2021-11-04
KR20210119469A (ko) 2021-10-05

Similar Documents

Publication Publication Date Title
US20220168392A1 (en) Methods of Enhancing Protection Against Organ and Vascular Injury, Hematopoietic Recovery and Survival in Response to Total Body Radiation/Chemical Exposure
EP3914272B1 (en) Thrombopoietin mimetics for mitigating liver injury and promoting liver hypertrophy, regeneration and cell engraftment in conjunction with radiation and/or radiomimetic treatments
KR102688415B1 (ko) 표적화된 방사선 치료요법에 의해 유도된 혈관 무결성을 보호하는 조성물
JP2012503014A (ja) マルチ−ｐｅｇ化顆粒球コロニー刺激因子（ｇ−ｃｓｆ）変異体の投与による放射線誘発好中球減少症の処置のための方法
JP2022523663A5 (https=)
Holmes-Hampton et al. PEGylated thrombopoietin mimetic, JNJ‑26366821 a novel prophylactic radiation countermeasure for acute radiation injury
Singh et al. α-Tocopherol succinate–and AMD3100-mobilized progenitors mitigate radiation-induced gastrointestinal injury in mice
DiCarlo et al. Role of thrombocytopenia in radiation-induced mortality and review of therapeutic approaches targeting platelet regeneration after radiation exposure
US20250312417A1 (en) Methods for Mitigating Lung Injury in Conjunction with Exposure to Radiation and/or Radiation or Radiomimetic Treatments
JP2021501750A (ja) 骨髄細胞の保護のためのアルファ−１−ミクログロブリンの使用
HK40064882B (en) Thrombopoietin mimetics for mitigating liver injury and promoting liver hypertrophy, regeneration and cell engraftment in conjunction with radiation and/or radiomimetic treatments
HK40064882A (en) Thrombopoietin mimetics for mitigating liver injury and promoting liver hypertrophy, regeneration and cell engraftment in conjunction with radiation and/or radiomimetic treatments
HK40033362A (en) Methods of protecting vascular integrity induced by targeted radiation therapy
HK1254810A1 (zh) 作為輻射緩和劑和輻射防護劑的bpi和其同源物的用途

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application